ClinicalTrials.gg
Sign In
RecruitingNCT07660731Updated Nov 3, 2026

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

A Phase 1 interventional study of PF-08103402 and Placebo in Healthy Volunteer Study, Healthy Adults and Healthy Participants, sponsored by Pfizer. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 3, 2026First site in Belgium1 site addedGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people.

For Parts A, B, C, D and F, the study is seeking participants who:

  • Are healthy (do not have disease) males or females who can no longer have children,
  • Are 18 to 65 years old,
  • Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a body weight of more than 50 kilograms (110 pounds). Body mass index is a way to measure body fat by using a person's height and weight

For Part A (optional group or cohort 3: Japanese participants only):

  • A body weight of more than 45 kilograms (100 pounds).
  • Have 4 biological Japanese grandparents who were born in Japan.

For Part E only:

  • Adults with a documented history of asthma (confirmed by a doctor) for at least 12 months before entering the study.
  • Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds).

The study has six parts: Part A, Part B, Part C, Part D, Part E and Part F. The study medicine will be taken as a suspension or tablet by mouth 1 time a day (except in Parts B and E where it will be taken 1 time a day for 14 days) at the study clinic. The study will help understand:

  • how the body processes the study medicine in healthy participants (Parts A and B),
  • how much of the study medicine gets into the bloodstream and if food affects the amount of study medicine in the blood in healthy participants (Part C),
  • how the study medicine is broken down and leaves the body in healthy participants (Optional Part D),
  • how the study medicine is processed in adults with mild-to-moderate asthma (Optional Part E),
  • if taking the study medicine together with another medicine affects how each medicine is processed by the body in healthy participants (Optional Part F).

Participants will take part in the study for about 10 weeks (Parts A and F), 12 weeks (Part B), 9 weeks (Parts C and D), and 16 weeks (Part E).

During this time, they will have 2 study visits at the study clinic and up to 28 overnight stays (Part A), 18 overnight stays (Parts B and E), 10 overnight stays (Part C), 11 overnight stays (Part D), and 16 overnight stays (Part F). The study team will also call participants 1 time over the phone at the end of the study to assess how they are doing.

Study measurements will be taken by body examination, monitoring side effects, blood and urine tests, heart tests (ECG), vital signs (blood pressure, pulse and respiratory rate), questionnaires (Parts C and E), stool samples (Part D only), and breathing tests (Part E only).

02

Conditions studied

  • Healthy Volunteer Study
  • Healthy Adults
  • Healthy Participants
  • Asthma

Browse trials for

Keywords

  • Human
  • Randomized
  • Metabolism
  • Excretion
  • Drug-Drug Interaction
  • Food effect
03

In context

Asthma

4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.

This study's planned enrollment of 133 is above the median of 78 across 3,341 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Pfizer is the lead sponsor of 3,334 studies on the registry; 149 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.

Browse Pfizer studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion criteria (Parts A, B, C, D and F):

  1. Are males or females who can no longer have children,
  2. Are 18 to 65 years old,
  3. Have a (BMI) of 16 to 32 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds).

For Part A (Optional group or cohort 3: Japanese participants only):

  1. A total body weight of more than 45 kg (100 pounds).
  2. Have 4 biological Japanese grandparents who were born in Japan.

For Part E only:

  1. Adults with a documented doctor's-diagnosis history of asthma for at least 12 months before entering the study.
  2. Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds).

Key Exclusion criteria

  1. Evidence or history of medical conditions.
  2. History of (HIV) infection, , or ; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb).
  3. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  4. Participation in studies of other products (drug or vaccine) at any time during their participation in this study.
  5. Any history of parasitic infection requiring treatment within 28 days prior to screening.
  6. Positive tuberculosis infection test result.
  7. Part C only: Evidence or history of conditions interfering with the ability to taste.
  8. Part D only: History of irregular bowel movements.
  9. Part E only: Evidence of lung disease(s) other than asthma.
  10. Part E only: Asthma exacerbation within 3 months prior to screening.
  11. Part F only: History of acute narrow-angle glaucoma, untreated open-angle glaucoma, sleep apnea, respiratory insufficiency, myasthenia gravis or adverse reaction to midazolam or other benzodiazepines.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
133 participants (estimated)

Study arms

  • Placebo comparator
    Part A: Cohorts 1, 2 and Optional Cohort 3

    PF-08103402 as suspensions (Cohorts 1 and 2)/tablets (Optional Cohort 3) or matching placebo as a single oral dose on Day 1 of each period

    Drug: PF-08103402 · Drug: Placebo

  • Placebo comparator
    Part B: Cohorts 4, 5, 6, 7, and Optional Cohort 8

    PF-08103402 as tablets or matching placebo given once daily oral doses from Day 1 through Day 14.

    Drug: PF-08103402 · Drug: Placebo

  • Other
    Part C: Cohort 9

    PF-08103402 as a single oral dose as tablets on Day 1 of each period

    Drug: PF-08103402

  • Other
    Part D: Cohort 10 (Optional)

    PF-08103402 as a single oral dose as tablets on Day 1.

    Drug: PF-08103402

  • Placebo comparator
    Part E: Cohorts 11 (Optional) and 12 (Optional)

    PF-08103402 as tablets or corresponding placebo as oral doses from Day 1 through Day 14.

    Drug: PF-08103402 · Drug: Placebo

  • Other
    Part F: Cohort 13 (Optional)

    Period 1: Single oral dose of midazolam on Day 1. Period 2: Once daily oral dose of PF-08103402 as tablets from Day 1 through Day 14 and a single oral dose of midazolam on Day 14 after the administration of PF-08103402.

    Drug: PF-08103402 · Drug: Midazolam

Interventions

  • DrugPF-08103402

    Oral suspension (Parts A to F); Tablets (Parts C and F only)

  • DrugPlacebo

    Oral suspension (Parts A, B and E).

  • DrugMidazolam

    Oral syrup

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional)

    Time frame: Parts A: Up to Day 36; Part B and E: Up to Day 50

  2. Number of Participants with Serious Adverse Events (SAEs)

    Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional)

    Time frame: Parts A: Up to Day 36; Part B and E: Up to Day 50

  3. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional)

    Time frame: Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional).

    Time frame: Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17

  5. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings

    Part A: Cohorts 1, 2 and Cohort 3 (optional). Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional). Part E: Cohorts 11 (optional) and 12 (optional).

    Time frame: Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17

  6. Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit, otherwise (AUClast) in the fasted state

    Part C: Cohort 9

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1

  7. Maximum observed plasma concentration (Cmax) in the fasted state

    Part C: Cohort 9

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1

  8. Total recovery of drug-related material in urine and feces separately, and both routes combined, expressed as a percent of total dose administered

    Part D: Cohort 10 (optional)

    Time frame: Pre-dose (Hour 0) and at 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)

  9. Maximum observed plasma concentration (Cmax)

    Part F: Cohort 13 (optional)

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 2, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)

  10. Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit, otherwise AUClast

    Part F: Cohort 13 (optional)

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 2, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)

Secondary outcomes

  1. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)

    Part A: Cohorts 1, 2 and Cohort 3 (optional).

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 and 36 hours post-dose (Day 2)

  2. Maximum observed plasma concentration (Cmax)

    Part A: Cohorts 1, 2 and Cohort 3 (optional).

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 and 36 hours post-dose (Day 2)

  3. Time of Maximum observed plasma concentration (Tmax)

    Part A: Cohorts 1, 2 and Cohort 3 (optional).

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 and 36 hours post-dose (Day 2)

  4. Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit

    Part A: Cohorts 1, 2 and Cohort 3 (optional).

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 and 36 hours post-dose (Day 2)

  5. Half-life (t½) if data permit

    Part A: Cohorts 1, 2 and Cohort 3 (optional)

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 and 36 hours post-dose (Day 2)

  6. Area under the curve over 1 dosing interval (AUCtau)

    Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional).

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1, Day 7 and Day 14

  7. Maximum observed plasma concentration (Cmax)

    Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional).

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1, Day 7 and Day 14

  8. Time of Maximum observed plasma concentration (Tmax)

    Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional).

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1, Day 7 and Day 14

  9. Half-life (t½) if data permit

    Part B: Cohorts 4, 5, 6, and 7 and Cohort 8 (optional).

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1, Day 7 and Day 14

  10. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Part C: Cohort 9

    Time frame: Up to Day 36

  11. Number of Participants With Serious Adverse Events (SAEs)

    Part C: Cohort 9

    Time frame: Up to Day 36

  12. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Part C: Cohort 9

    Time frame: Change From Baseline to Day 4

  13. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Part C: Cohort 9

    Time frame: Change From Baseline to Day 4

  14. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings

    Part C: Cohort 9

    Time frame: Change From Baseline to Day 4

  15. Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Part D: Cohort 10 (optional)

    Time frame: Up to Day 36

  16. Number of Participants With Serious Adverse Events (SAEs)

    Part D: Cohort 10 (optional)

    Time frame: Up to Day 36

  17. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

    Part D: Cohort 10 (optional)

    Time frame: Change From Baseline to Day 11

  18. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Part D: Cohort 10 (optional)

    Time frame: Change From Baseline to Day 11

  19. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings

    Part D: Cohort 10 (optional)

    Time frame: Change From Baseline to Day 11

  20. Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit, otherwise AUClast

    Part D: Cohort 10 (optional)

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1, 24 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4), 96 hours post-dose (Day 5), 120 hours post-dose (Day 6), 144 hours post-dose (Day 7)

  21. Maximum observed plasma concentration (Cmax)

    Part D: Cohort 10 (optional)

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1, 24 hours post-dose (Day 2), 48 hours post-dose (Day 3), 72 hours post-dose (Day 4), 96 hours post-dose (Day 5), 120 hours post-dose (Day 6), 144 hours post-dose (Day 7).

  22. Change From Baseline (CFB) in Fractional concentration of exhaled Nitric Oxide (FeNO) at Day 14

    Part E: Cohorts 11 (optional) and 12 (optional)

    Time frame: Pre-dose (Hour 0) and at 72 hours post-dose (Day 4), 144 hours post-dose (Day 7), 264 hours post-dose (Day 12), 312 hours post-dose (Day 14) and 384 hours post-dose (Day 17)

  23. Area under the curve over 1 dosing interval (AUCtau)

    Part E: Cohorts 11 (optional) and 12 (optional)

    Time frame: Pre-dose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose (Day 1); 24 hours post-dose (Day 2); 144 hours post-dose (Day 7); 312 hours post-dose (Day 14); 336 hours post-dose (Day 15); 360 hours post-dose (Day 16); 384 hours post-dose (Day 17)

  24. Maximum observed plasma concentration (Cmax)

    Part E: Cohorts 11 (optional) and 12 (optional)

    Time frame: Pre-dose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose (Day 1); 24 hours post-dose (Day 2); 144 hours post-dose (Day 7); 312 hours post-dose (Day 14); 336 hours post-dose (Day 15); 360 hours post-dose (Day 16); 384 hours post-dose (Day 17)

  25. Time of Maximum observed plasma concentration (Tmax)

    Part E: Cohorts 11 (optional) and 12 (optional)

    Time frame: Pre-dose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose (Day 1); 24 hours post-dose (Day 2); 144 hours post-dose (Day 7); 312 hours post-dose (Day 14); 336 hours post-dose (Day 15); 360 hours post-dose (Day 16); 384 hours post-dose (Day 17)

  26. Half-life (t½) if data permit

    Part E: Cohorts 11 (optional) and 12 (optional)

    Time frame: Pre-dose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose (Day 1); 24 hours post-dose (Day 2); 144 hours post-dose (Day 7); 312 hours post-dose (Day 14); 336 hours post-dose (Day 15); 360 hours post-dose (Day 16); 384 hours post-dose (Day 17)

  27. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Part F: Cohort 13 (optional)

    Time frame: Up to Day 51

  28. Number of Participants With Serious Adverse Events (SAEs)

    Part F: Cohort 13 (optional)

    Time frame: Up to Day 51

  29. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Part F: Cohort 13 (optional)

    Time frame: Change From Baseline to Day 16

  30. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings

    Part F: Cohort 13 (optional)

    Time frame: Change From Baseline to Day 16

  31. Area under the curve over 1 dosing interval (AUCtau)

    Part F: Cohort 13 (optional)

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)

  32. Maximum observed plasma concentration (Cmax)

    Part F: Cohort 13 (optional)

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1 (Period 1 ) and on Day 1 and Day 14 (Period 2)

  33. Time of Maximum observed plasma concentration (Tmax)

    Part F: Cohort 13 (optional)

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1 (Period 1 ) and on Day 1 and Day 14 (Period 2)

  34. Half-life (t½) if data permit

    Part F: Cohort 13 (optional)

    Time frame: Pre-dose (Hour 0) and at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose on Day 1 (Period 1 ) and on Day 1 and Day 14 (Period 2)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2027, 9 months after the start.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 9 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Belgium
Show site
  • Pfizer Clinical Research Unit - Brussels · Brussels, Belgium
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    1 site added — first site in Belgium
    Show site
    • Pfizer Clinical Research Unit - Brussels · Brussels, Belgium
    + 1 other change: verification date
  2. Oct 13, 2026
    Minor edits only
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07660731
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jun 17, 2026
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Asthma →

Other studies from this sponsor

Pfizer →

Start the discussion